Table 2.

Pairwise ranking of dual targets.

NB non-Aa		F-valueb	p Valuec	NB MYCNAd		F-value	p Value
ALK_NTRK1		380	7.0 E−51	ACVR2B_GFRA3		193	2.8 E−30
GFRA3_ALK	1	380	7.2 E−51	GFRA3_ALK	1	142	2.9 E−26
GFRA3_NTRK1		334	3.9 E−48	CDH24_ACVR2B		132	2.4 E−25
NTRK1_GFRA2		333	4.5 E−48	ACVR2B_GFRA2		125	1.4 E−24
SDK1_NTRK1		281	1.5 E−44	ACVR2B_ALK		118	6.7 E−24
GFRA3_GPR173	2	268	1.3 E−43	CDH24_ALK	5	115	1.5 E−23
GFRA2_GFRA3	3	263	3.3 E−43	MC1R_ACVR2B		113	2.0 E−23
ALK_INSRR		262	3.5 E−43	ACVR2B_GPR173		109	6.5 E−23
GPR173_NTRK1		256	1.2 E−42	GFRA3_CELSR3		108	8.2 E−23
PCDHB6_NTRK1		253	2.0 E−42	CELSR3_ACVR2B		107	1.2 E−22
PTPRH_NTRK1		247	5.5 E−42	GFRA3_GPR173	2	97	1.4 E−21
INSRR_GFRA3		243	1.1 E−41	ALK_MC1R		89	1.5 E−20
CDH24_NTRK1		232	1.1 E−40	GFRA2_ALK	4	84	7.2 E−20
GFRA3_PTPRH		230	1.5 E−40	ALK_GPR173	6	82	1.4 E−19
INSRR_NTRK1		227	2.9 E−40	GFRA2_GFRA3	3	82	1.3 E−19
INSRR_GFRA2		221	9.3 E−40	GFRA3_CDH24		82	1.5 E−19
GFRA3_PCDHB6		220	2.7 E−38	CELSR3_ALK		76	8.1 E−19
GFRA2_ALK	4	213	4.5 E−39	GFRA2_CDH24	8	73	2.8 E−18
PTPRH_ALK		211	6.6 E−39	CDH24_CELSR3		70	7.8 E−18
SDK1_ALK		205	2.7 E−38	GPR173_GFRA2	7	63	9.7 E−17
CDH24_GFRA3		199	1.1 E−37	GFRA2_CELSR3		61	2.1 E−16
CDH24_ALK	5	198	1.1 E−37	GPR173_CDH24	9	60	2.3 E−16
GFRA3_SDK1		192	4.1 E−37	MC1R_GFRA3		60	2.6 E−16
ALK_GPR173	6	180	7.5 E−36	CDH24_MC1R		57	8.5 E−16
INSRR_PTPRH		180	8.1 E−36	MC1R_GFRA2		57	8.5 E−16
PCDHB6_ALK		180	7.9 E−36	GPR173_CELSR3		54	3.7 E−15
INSRR_GPR173		171	1.8 E−33	MC1R_CELSR3		51	1.0 E−14
INSRR_PCDHB6		158	1.8 E−33	GPR173_MC1R		50	1.4 E−14
INSRR_SDK1		153	6.3 E−33
GFRA2_PTPRH		150	1.7 E−32
PCDHB6_GFRA2		146	4.8 E−32
INSRR_CDH24		142	1.7 E−31
GPR173_GFRA2	7	140	2.4 E−31
PTPRH_PCDHB6		134	1.3 E−30
GPR173_PTPRH		130	4.6 E−30
SDK1_PTPRH		130	2.0 E−30
SDK1_GFRA2		128	8.1 E−30
SDK1_GPR173		128	9.3 E−30
CDH24_GFRA2	8	123	6.0 E−29
SDK1_PCDHB6		111	2.0 E−27
CDH24_PTPRH		106	1.1 E−26
GPR173_PCDHB6		99	1.4 E−25
CDH24_SDK1		97	2.6 E−25
GPR173_CDH24	9	95	6.3 E−25
CDH24_PCDHB6		81	1.8 E−22

Dual targets (hits) with favorable cell surface expression characteristics (Table 1) were ranked from the neuroblastoma without MYCN gene amplification^a or with MYCN gene amplification^d data sets according to MANOVA F-value^b. Also listed is the MANOVA p-value^c for each pair. In gray boxes, the nine shared antigen pairs shared between both types are indicated.